China Medical System Holdings Ltd banner
C

China Medical System Holdings Ltd
HKEX:867

Watchlist Manager
China Medical System Holdings Ltd
HKEX:867
Watchlist
Price: 13.09 HKD -4.66% Market Closed
Market Cap: HK$31.9B

China Medical System Holdings Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Medical System Holdings Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
HKEX:867
Cash from Operating Activities
¥758.4m
CAGR 3-Years
-40%
CAGR 5-Years
-22%
CAGR 10-Years
2%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
¥4.8B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
¥11.2B
CAGR 3-Years
107%
CAGR 5-Years
27%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
¥4.6B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
8%
Zhejiang Nhu Co Ltd
SZSE:002001
Cash from Operating Activities
¥8.8B
CAGR 3-Years
26%
CAGR 5-Years
23%
CAGR 10-Years
25%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
¥4.1B
CAGR 3-Years
N/A
CAGR 5-Years
171%
CAGR 10-Years
N/A
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
31.9B HKD
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a notable player in the Chinese pharmaceutical landscape, has woven a strategy that cleverly integrates proprietary drug development with a robust marketing apparatus. Established in 1995 and headquartered in Shenzhen, the company has developed a knack for identifying pharmaceuticals and medical devices with promising potential. Their business model hinges on acquiring exclusive rights to a carefully curated portfolio of international products, which they then introduce to the burgeoning Chinese market. By leveraging their deep understanding of market dynamics and regulatory environments, they effectively roll out these products, ensuring that they meet local demand and adhere to high compliance standards. The company's revenue engine is powered predominantly by its dynamic sales and marketing network which spans across mainland China. They employ a multifaceted distribution model, partnering with an extensive range of hospitals and healthcare providers to facilitate widespread adoption of their products. But what truly sets China Medical System Holdings apart is its focus on products that are already well advanced within their lifecycle, minimizing the usual risks associated with early-stage pharmaceutical development. This strategic approach not only ensures steady cash flows but also reduces overhead costs associated with R&D, allowing them to reinvest profits into acquiring new products and expanding their market footprint. As such, their business thrives on a cycle of discernment and targeted expansion, positioning them as a formidable entity in the healthcare sector.

Intrinsic Value
17.06 HKD
Undervaluation 23%
Intrinsic Value
Price HK$13.09
C

See Also

What is China Medical System Holdings Ltd's Cash from Operating Activities?
Cash from Operating Activities
758.4m CNY

Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Cash from Operating Activities amounts to 758.4m CNY.

What is China Medical System Holdings Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
2%

Over the last year, the Cash from Operating Activities growth was -40%. The average annual Cash from Operating Activities growth rates for China Medical System Holdings Ltd have been -40% over the past three years , -22% over the past five years , and 2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett